Long-term survival in a young patient with anaplastic glioma.
A 26-year-old man with anaplastic glioma in the left frontoparietal lobe survived for 9 years and 9 months after combined therapy, including subtotal resection, postoperative irradiation, and chemotherapy. The tumor recurred and he received immunotherapy using lymphokine-activated killer (LAK) cells. At the last LAK cell infusion, infection of the Ommaya reservoir occurred, but subsided after antibiotics were administered. Follow-up neuroimaging showed no recurrence of the tumor. Review of the surgical specimens found that the original diagnosis of glioblastoma was inconclusive, although the tumor is considered to be a type of anaplastic glioma.
Naganuma
H
H
Department of Neurosurgery, Yamanashi Medical University, Japan.
Sasaki
A
A
Satoh
E
E
Nagasaka
M
M
Isoe
S
S
Nakano
S
S
Nukui
H
H
D000328:Adult; D015415:Biomarkers / Q000032:analysis; D001932:Brain Neoplasms / Q000401:mortality / Q000473:pathology* / Q000628:therapy; D003131:Combined Modality Therapy; D005910:Glioma / Q000401:mortality / Q000473:pathology* / Q000628:therapy; D006801:Humans; D007150:Immunohistochemistry; D007167:Immunotherapy; D015979:Killer Cells, Lymphokine-Activated / Q000276:immunology; D008297:Male; D010296:Parietal Lobe / Q000737:chemistry / Q000000981:diagnostic imaging / Q000473:pathology*; D014057:Tomography, X-Ray Computed
D015415:Biomarkers